{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05653271",
            "orgStudyIdInfo": {
                "id": "ACE1831-001"
            },
            "organization": {
                "fullName": "Acepodia Biotech, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies",
            "officialTitle": "A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated Gamma Delta T-cell Therapy, in Adult Subjects With Relapsed/Refractory CD20-expressing B-cell Malignancies",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "in-adult-subjects-with-relapsed-refractory-expressing-b-cell-malignancies"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-01-21",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-11-02",
            "studyFirstSubmitQcDate": "2022-12-07",
            "studyFirstPostDateStruct": {
                "date": "2022-12-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-27",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-28",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Acepodia Biotech, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies.\n\nThe ACE1831-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and efficacy of ACE1831 in patients with CD20-expressing Non-Hodgkin lymphoma."
        },
        "conditionsModule": {
            "conditions": [
                "B-cell Lymphoma",
                "Non Hodgkin Lymphoma",
                "DLBCL",
                "Primary Mediastinal Large B Cell Lymphoma",
                "Marginal Zone Lymphoma",
                "Follicular Lymphoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 42,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Treatment Group A (ACE1831)",
                    "type": "EXPERIMENTAL",
                    "description": "ACE1831 dose escalation, monotherapy. Lymphodepleting regimen followed by escalating doses of ACE1831.",
                    "interventionNames": [
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: ACE1831"
                    ]
                },
                {
                    "label": "Treatment Group B (ACE1831 and obinutuzumab)",
                    "type": "EXPERIMENTAL",
                    "description": "ACE1831 dose escalation, in combination with obinutuzumab. Lymphodepleting regimen followed by escalating doses of ACE1831, given in combination with obinutuzumab.",
                    "interventionNames": [
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: ACE1831",
                        "Drug: Obinutuzumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "Lymphodepleting agent",
                    "armGroupLabels": [
                        "Treatment Group A (ACE1831)",
                        "Treatment Group B (ACE1831 and obinutuzumab)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fludarabine",
                    "description": "Lymphodepleting agent",
                    "armGroupLabels": [
                        "Treatment Group A (ACE1831)",
                        "Treatment Group B (ACE1831 and obinutuzumab)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "ACE1831",
                    "description": "Allogeneic gamma delta T (gdT) cell therapy",
                    "armGroupLabels": [
                        "Treatment Group A (ACE1831)",
                        "Treatment Group B (ACE1831 and obinutuzumab)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Obinutuzumab",
                    "description": "Anti-CD20 monoclonal antibody",
                    "armGroupLabels": [
                        "Treatment Group B (ACE1831 and obinutuzumab)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of adverse events (AEs), Dose Limiting Toxicities (DLTs), adverse events of special interest (AESIs), and serious adverse events (SAEs)",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Change from baseline in ECOG status",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Change from baseline in physical examination results",
                    "description": "Number of subject with change from baseline clinically significant physical examination findings by dose level (descriptive)",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Change from baseline clinical laboratory tests results",
                    "description": "Number of subjects with change from baseline clinically significant lab findings by dose level (descriptive)",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Change from baseline in urinalysis results",
                    "description": "Number of subjects with change from baseline clinically significant urinalysis findings by dose level (descriptive)",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Change from baseline in vital signs results",
                    "description": "Number of subjects with change from baseline clinical significant vital signs findings by dose level (descriptive)",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Change from baseline in electrocardiogram (ECG) results",
                    "description": "Number of subjects with change from baseline clinically significant ECG findings by dose level (descriptive)",
                    "timeFrame": "1 month"
                },
                {
                    "measure": "Maximum Tolerated Dose (MTD)",
                    "timeFrame": "1 month"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Persistence of ACE1831 after administration",
                    "description": "Half-life of ACE1831",
                    "timeFrame": "1 month"
                },
                {
                    "measure": "Measure of anti-ACE1831 antibodies after administration",
                    "description": "Titration of anti-ACE1831 antibodies after administration",
                    "timeFrame": "1 month"
                },
                {
                    "measure": "Objective Response Rate (ORR)",
                    "description": "Objective response of each patient's underlying lymphoma, duration of response, and progression-free survival all based on the revised IWG Response Criteria for Malignant Lymphoma",
                    "timeFrame": "2 years"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Pharmacodynamics of ACE1831",
                    "description": "Serum levels of interferon-\u03b3, TNF-\u03b1, IL-2, IL-6, IL-8 and IL-10, as well as other potential biomarkers",
                    "timeFrame": "2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* CD20-positive B-cell NHL that is persistent or progressive after having received at least 2 prior systemic therapies per NCCN guidelines\n* At least 1 measurable lesion according to the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1\n* Adequate hematologic and renal, hepatic, and cardiac function\n* Oxygen saturation via pulse oxygenation \u2265 92% at rest on room air\n\nKey Exclusion Criteria:\n\n* Prior treatment with a genetically modified cell therapy product targeting CD20\n* Autologous stem cell transplant within 6 weeks of informed consent or history of allogeneic stem cell transplantation\n* History of central nervous system (CNS) lymphoma or primary CNS lymphoma\n* History or presence of clinically relevant CNS disorder (e.g. epilepsy)\n* Clinically significant active infection\n* Currently active, clinically significant cardiovascular disease\n* Human Immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection\n* History of other malignancies with the exception of certain treated malignancies with no evidence of disease\n* Primary immunodeficiency disorder\n* Pregnant or lactating female\n* Any medical, psychological, familial, or sociological conditions that, in the opinion of the Investigator or Sponsor Medical Monitor, would impair the ability of the subject to receive study treatment, comply with study requirements, or understanding of the informed consent",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Stephanie Chien",
                    "role": "CONTACT",
                    "phone": "+1 415-366-7822",
                    "email": "clinical@acepodiabio.com"
                }
            ],
            "locations": [
                {
                    "facility": "AdventHealth Orlando",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32804",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Rushang D Patel, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "Emory University",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30322",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jason Romancik, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "Indiana University Simon Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Varun Mittal, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                },
                {
                    "facility": "Norton Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Louisville",
                    "state": "Kentucky",
                    "zip": "40207",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Don A Stevens, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.25424,
                        "lon": -85.75941
                    }
                },
                {
                    "facility": "The University of Texas MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ranjit Nair, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Tamsui MacKay Memorial Hospital",
                    "status": "RECRUITING",
                    "city": "New Taipei City",
                    "country": "Taiwan",
                    "contacts": [
                        {
                            "name": "Yi-Fang Chang, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.01111,
                        "lon": 121.44583
                    }
                },
                {
                    "facility": "Linkou Chang-Gung Memorial Hospital",
                    "status": "RECRUITING",
                    "city": "Taoyuan City",
                    "country": "Taiwan",
                    "contacts": [
                        {
                            "name": "Doung-Liang Lin, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 24.95233,
                        "lon": 121.20193
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000016393",
                    "term": "Lymphoma, B-Cell"
                },
                {
                    "id": "D000018442",
                    "term": "Lymphoma, B-Cell, Marginal Zone"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000008228",
                    "term": "Lymphoma, Non-Hodgkin"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18828",
                    "name": "Lymphoma, B-Cell",
                    "asFound": "B-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11221",
                    "name": "Lymphoma, Follicular",
                    "relevance": "LOW"
                },
                {
                    "id": "M20554",
                    "name": "Lymphoma, B-Cell, Marginal Zone",
                    "asFound": "Marginal zone lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11222",
                    "name": "Lymphoma, Non-Hodgkin",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T640",
                    "name": "B-cell Lymphoma",
                    "asFound": "B-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2361",
                    "name": "Follicular Lymphoma",
                    "asFound": "Follicular lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3612",
                    "name": "Marginal Zone Lymphoma",
                    "asFound": "Marginal zone lymphoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                },
                {
                    "id": "C000543332",
                    "term": "Obinutuzumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M288906",
                    "name": "Obinutuzumab",
                    "asFound": "Plate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}